Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Novel Approaches to the Management of Non-Hodgkin Lymphoma

Novel Approaches to the Management of Non-Hodgkin Lymphoma The rate of increase in the incidence of non-Hodgkin lymphoma (NHL) is outstripping that of other cancers. NHL is increasingly being treated in the context of immune compromise due to age or concomitant disease. Whilst most NHLs fall into the clearly aggressive and indolent categories, it is clear that distinction of less common entities such as Burkitt and mucosa-associated lymphoid tissue (MALT) lymphomas is essential for appropriately targeted treatment. Better diagnostic tools including the WHO histopathological criteria and quality imaging systems for CT, magnetic resonance imaging (MRI), and positron emission tomography (PET) scanning have facilitated accurate disease classification. Prognostic indices have been validated for both aggressive and indolent disease, and multidisciplinary input into diagnosis and management has proved beneficial. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Novel Approaches to the Management of Non-Hodgkin Lymphoma

Loading next page...
 
/lp/springer-journals/novel-approaches-to-the-management-of-non-hodgkin-lymphoma-Z3kEP30kza
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504030-00002
Publisher site
See Article on Publisher Site

Abstract

The rate of increase in the incidence of non-Hodgkin lymphoma (NHL) is outstripping that of other cancers. NHL is increasingly being treated in the context of immune compromise due to age or concomitant disease. Whilst most NHLs fall into the clearly aggressive and indolent categories, it is clear that distinction of less common entities such as Burkitt and mucosa-associated lymphoid tissue (MALT) lymphomas is essential for appropriately targeted treatment. Better diagnostic tools including the WHO histopathological criteria and quality imaging systems for CT, magnetic resonance imaging (MRI), and positron emission tomography (PET) scanning have facilitated accurate disease classification. Prognostic indices have been validated for both aggressive and indolent disease, and multidisciplinary input into diagnosis and management has proved beneficial.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References